Earnings ·
Pacific Biosciences of California announced Q2 2026 financial results with total revenue of $39.0 million and a GAAP…
PACBPacific Biosciences of California, Inc.
Pacific Biosciences of California announced Q2 2026 financial results with total revenue of $39.0 million and a GAAP net loss of $44.7 million, while providing full-year 2026 revenue guidance of $155 million to $165 million. The Board approved a restructuring plan targeting the elimination of approximately 8% of its workforce (40 employees) to reduce annualized operating expenses by $30 million to $40 million by end-2027, incurring estimated pre-tax charges of $2.0 million. Concurrently, Mark Van Oene succeeded Christian Henry as President and CEO effective August 5, 2026. Van Oene’s compensation includes a $743,000 base salary and equity grants valued at $2.25 million, while Henry will serve as Senior Business Advisor through December 31, 2026, with a separation payment of approximately $1.16 million upon transition completion. Pacific Biosciences operates in the life science technology industry, designing and manufacturing advanced genomic sequencing solutions.